Dong-A ST's Significant Milestone for IMULDOSA
Dong-A ST recently made headlines with the favorable recommendation for its biosimilar IMULDOSA (active ingredient: ustekinumab), which has been developed to offer an alternative to the original Stelara. This monumental achievement was facilitated by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which provided a positive opinion regarding the product's Marketing Authorisation Application (MAA).
Details on the Recommendation
The favorable CHMP recommendation is a crucial step in the approval process, which evaluates potential medications systematically based on rigorous scientific assessments of quality, safety, and efficacy. This recommendation is instrumental for the European Commission (EC) as it deliberates on whether to grant official marketing authorization for IMULDOSA in the European Union.
Partnerships and Development History
The development of IMULDOSA began in 2013, with a collaborative effort between Dong-A Socio Holdings and Meiji Seika Pharma. In 2020, Dong-A ST assumed full control of the R&D and commercialization responsibilities, thereby streamlining the project management necessary for successful product delivery and innovative outcomes. The strategic decision to enter a global licensing agreement with Intas Pharmaceuticals in 2021 paved the way for its commercial development, which includes operations through Accord BioPharma in the United States.
Market Potential and Competitive Advantage
With the global sales of Stelara reaching an impressive total of US$19 billion, including US$3.2 billion from Europe alone, the potential market for IMULDOSA is substantial. Given this context, IMULDOSA aims to provide patients with new treatment options for various immunological conditions, potentially broadening patient access to care that was previously limited to Stelara.
Recent Achievements and Future Outlook
This recent positive CHMP opinion follows Dong-A ST's earlier triumph in obtaining FDA approval for IMULDOSA, which took place on October 10. These accomplishments highlight the company's commitment to advancing biotech solutions and its dedication to developing therapies that improve patient outcomes worldwide.
Commitment to Patients
Dong-A ST's leadership emphasizes its focus on successfully launching IMULDOSA across both US and European markets. The recognition from the CHMP reinforces Dong-A ST’s R&D expertise and paves the way for patients globally to benefit from improved alternatives in immunology treatments. This dedication underscores Dong-A ST's standing as an emerging leader in the biopharmaceutical industry.
Frequently Asked Questions
What is IMULDOSA?
IMULDOSA is a biosimilar developed by Dong-A ST that aims to treat various immunology conditions.
What is the significance of the CHMP recommendation?
The CHMP recommendation is critical for securing marketing authorization in the European Union, moving IMULDOSA closer to market availability.
How does IMULDOSA compare to Stelara?
IMULDOSA is positioned as an alternative to Stelara, offering similar therapeutic benefits for treating immunological conditions.
What partnerships support IMULDOSA's development?
Dong-A ST collaborates with Intas Pharmaceuticals for the commercialization of IMULDOSA, ensuring effective market penetration.
What are the next steps for IMULDOSA?
Following the positive recommendations, Dong-A ST is focused on launching IMULDOSA successfully in both US and European markets.
